Search hospitals
>
Pennsylvania
>
Wynnewood
Lankenau Medical Center
Claim this profile
Wynnewood, Pennsylvania 19096
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
346 reported clinical trials
22 medical researchers
Summary
Lankenau Medical Center is a medical facility located in Wynnewood, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. Lankenau Medical Center is involved with conducting 346 clinical trials across 377 conditions. There are 22 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, William Gray, MD, and Deric C. Savior.
Area of expertise
Lung Cancer
Lankenau Medical Center has run 65 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Lankenau Medical Center has run 58 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Albert DeNittis, MD
Lankenau Medical Center
5 years of reported clinical research
Paul B. Gilman
Riddle Memorial Hospital
5 years of reported clinical research
William Gray, MD
Lankenau Medical Center
7 years of reported clinical research
Deric C. Savior
Paoli Memorial Hospital
11 years of reported clinical research
Clinical Trials running at Lankenau Medical Center
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Breast cancer
Ovarian Cancer
Cancer
Uterine Cancer
Small Cell Lung Cancer
Pancreatic Cancer
Endometrial Cancer
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lankenau Medical Center?
Lankenau Medical Center is a medical facility located in Wynnewood, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Ovarian Cancer and other specialties. Lankenau Medical Center is involved with conducting 346 clinical trials across 377 conditions. There are 22 research doctors associated with this hospital, such as Albert DeNittis, MD, Paul B. Gilman, William Gray, MD, and Deric C. Savior.
Where is Lankenau Medical Center located?
To reach Lankenau Medical Center in Wynnewood, Pennsylvania: 1. Take I-95 to I-676/76 West in Philadelphia. 2. Exit onto City Avenue and head south on Route 1 (City Line Avenue) to the intersection of Route 30 (Lancaster Avenue). 3. Turn right onto Lancaster Avenue; the hospital will be on your left. Alternatively, utilize GPS navigation services like Waze for real-time directions.
Who should I call to ask about financial aid or insurance network?
**Lankenau Medical Center Financial Assistance:** - Contact the Main Line Health Business office at 484.337.1970 for financial assistance inquiries. - Financial assistance is available based on annual income and household size, with 100% assistance for those with income 300% or less of the federal poverty guidelines, and significant discounts for those with income between 300% and 500%. - Financial counselors are available to assist with the application process. **NYU Langone Health Insurance Information:** - Visit the NYU Langone Health website for detailed information on insurance, billing, and financial assistance. - It's recommended to consult with your insurance company for accurate out-of-pocket costs for services at NYU Langone. - In emergency situations or when treated by an out-of-network provider at an in-network hospital, you're protected from being charged beyond your plan’s copayments, coinsurance, or deductible.
What insurance does Lankenau Medical Center accept?
Lankenau Medical Center, part of Main Line Health, accepts a broad spectrum of health insurance plans. This includes commercial plans such as Aetna, Cigna, Capital Blue Cross, Highmark Blue Shield, Independence Blue Cross, and United Healthcare. They also welcome Medicare Advantage plans like Advantra Medicare (Aetna), Humana Medicare Advantage, and USA MCO, in addition to Medicaid MCO plans such as AmeriHealth Caritas and PA Health and Wellness.
What awards or recognition has Lankenau Medical Center received?
Lankenau Medical Center has been awarded a Silver Milestone recognition by the Intersocietal Accreditation Commission (IAC) for 25 years of IAC Echocardiography accreditation. It was also ranked No. 168 in Newsweek's list of the nation's best hospitals, recognized for attracting top talent, delivering excellent patient outcomes, and pioneering advanced therapies and research.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.